Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
316.27
-0.56 (-0.18%)
At close: Nov 12, 2026, 4:00 PM EST
317.00
+0.73 (0.23%)
After-hours: Nov 12, 2026, 7:59 PM EST
Ligand Pharmaceuticals Revenue
Ligand Pharmaceuticals had revenue of $78.75M in the quarter ending September 30, 2026, a decrease of -31.80%. This brings the company's total for the last twelve months to $253.83M, up 1.03% year-over-year. In the year 2025, Ligand Pharmaceuticals had annual revenue of $268.09M with 60.40% growth. That makes Ligand Pharmaceuticals the 15,751st largest company in the world by revenue and 2,720th in the United States.
Revenue (ttm)
$253.83M
Revenue Growth
+1.03%
P/S Ratio
24.92
Revenue / Employee
$5,400,574
Employees
47
Market Cap
6.33B
Revenue by Segment
- Revenue from Intangible Royalty Assets 132.53M 49.4%
- Contract Revenue and Income 66.87M 24.9%
- Captisol 40.21M 15.0%
- Income from Financial Royalty Assets 28.47M 10.6%
Fiscal year ended Dec 31, 2025 See the full Ligand Pharmaceuticals breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 268.09M | 100.95M | 60.40% |
| Dec 31, 2024 | 167.13M | 35.82M | 27.28% |
| Dec 31, 2023 | 131.31M | -64.93M | -33.09% |
| Dec 31, 2022 | 196.25M | -45.30M | -18.75% |
| Dec 31, 2021 | 241.54M | 77.98M | 47.68% |
| Dec 31, 2020 | 163.56M | 43.28M | 35.98% |
| Dec 31, 2019 | 120.28M | -131.17M | -52.17% |
| Dec 31, 2018 | 251.45M | 110.35M | 78.21% |
| Dec 31, 2017 | 141.10M | 32.13M | 29.48% |
| Dec 31, 2016 | 108.97M | 37.06M | 51.53% |
| Dec 31, 2015 | 71.91M | 7.38M | 11.43% |
| Dec 31, 2014 | 64.54M | 15.57M | 31.78% |
| Dec 31, 2013 | 48.97M | 17.59M | 56.02% |
| Dec 31, 2012 | 31.39M | 1.35M | 4.50% |
| Dec 31, 2011 | 30.04M | 6.50M | 27.61% |
| Dec 31, 2010 | 23.54M | -15.40M | -39.55% |
| Dec 31, 2009 | 38.94M | 11.63M | 42.56% |
| Dec 31, 2008 | 27.32M | 14.42M | 111.84% |
| Dec 31, 2007 | 12.89M | 8.92M | 224.21% |
| Dec 31, 2006 | 3.98M | -6.24M | -61.07% |
| Dec 31, 2005 | 10.22M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Caris Life Sciences | 1.05B |
| Mirum Pharmaceuticals | 670.78M |
| Arrowhead Pharmaceuticals | 669.50M |
| ImmunityBio | 182.57M |
| CG Oncology | 6.17M |
| Scholar Rock Holding | 570.00K |
LGND News
- 1 day ago - Ligand price target raised to $350 from $345 at Barclays - TheFly
- 7 days ago - Ligand price target raised to $402 from $397 at Citi - TheFly
- 13 days ago - Ligand price target raised to $346 from $334 at Oppenheimer - TheFly
- 13 days ago - Ligand price target raised to $350 from $332 at Stifel - TheFly
- 14 days ago - Ligand Pharmaceuticals Earnings Call Transcript: Q3 2026 - Transcripts
- 14 days ago - Ligand Pharmaceuticals Earnings release: Q3 2026 - Filings
- 14 days ago - Ligand Pharmaceuticals Slides: Q3 2026 - Filings
- 14 days ago - Ligand Pharmaceuticals Quarterly report: Q3 2026 - Filings